S1130525060003 gantanhuan gjzq.com.cn AI + + 投资逻辑 本周蚂蚁阿福 APP 上市后高流量带动下医疗 AI 主题关注度较高。此前互联网医疗痛点来自于 1）远程平台客户粘性 不足，活跃用户比例较低；2）优质医疗资源有限。而蚂蚁阿福从 AI 工具到 AI 朋友全面升级，并上线健康陪伴、健 康问答、健康服务三大功能。健康陪伴功能通过高频健康管理的方式很好的解决了此前客户粘性问题，同时也成为链 接患者与药品、终端服务的入口。此外平台，链接了全国 5000 家医院和 30 万真人医生，拥有六位国家院士领衔的全 国 500 多位名医开设的'AI 分身'，实现优质医疗资源"平民化"。我们认为蚂蚁阿福是 AI 医疗规模化市场与可行商 业模式再验证，同时平台流量有望为"医+药+险"全链条赋能。 药品板块：12 月 18 日，武田宣布其 TYK2 抑制剂 Zasocitinib 针对中重度斑块状银屑病的 2 项注册 III 期临床中达 到所有主要与次要终点。第 16 周时 ZASO 组超过一半患者实现 PASI 90，平均约 30%患者实现 PASI 100。武田制药计 划在即将举行的 ...

Core Insights - President Trump announced a set of drug-pricing agreements with nine major pharmaceutical companies, aiming to align U.S. medicine costs with those in Europe [1][2] - The initiative includes a new direct-to-consumer portal, TrumpRx.gov, allowing patients to purchase certain medicines directly from manufacturers [2][4] Group 1: Agreements and Participants - The agreements involve 14 out of 17 drugmakers that Trump previously urged to lower prices, including Amgen, GSK, and Merck [2][3] - Drug companies are motivated to negotiate to avoid potential regulatory measures that could impact their profits [3] Group 2: TrumpRx.gov Functionality - TrumpRx.gov will serve as a central directory for patients to access selected medicines directly from manufacturers' websites [4] - The portal is expected to be fully operational by January, following a promotional launch [4] Group 3: Pricing Details - Highlighted medicines include Amgen's Repatha at $239/month, GSK's Advair Diskus at $89/month, and Merck's Januvia at $100/month [6] - Gilead's Epclusa will be priced at $2,492/month, despite lower costs for insured patients [6] Group 4: Impact on Medicaid and Medicare - Companies committed to launching new medicines in the U.S. at prices comparable to those in other wealthy countries [8] - Medicaid programs are legally entitled to the lowest drug prices, with Bristol Myers Squibb offering Eliquis free to Medicaid [9] Group 5: Industry Response and Future Outlook - Health policy experts express skepticism about the agreements' impact on overall drug prices for most Americans [10] - The agreements do not impose mandatory price controls and leave many brand-name drug costs unchanged [15] - Ongoing discussions with additional manufacturers like AbbVie and Johnson & Johnson may lead to further agreements [14]

Core Insights - Donald Trump and nine major pharmaceutical companies have reached agreements to significantly reduce drug prices for the Medicaid program and cash payers, aiming to align US costs with those in other wealthy nations [1][2] Group 1: Price Reductions and Agreements - Drugmakers will cut prices on most drugs sold to Medicaid, promising "massive savings" on commonly used medicines, although specific figures were not disclosed [2] - The deals include agreements to lower cash-pay prices for select drugs, launch drugs in the US at prices equal to those in other wealthy nations, and increase manufacturing [3] - Merck plans to sell its diabetes drugs at approximately 70% off list prices directly to US consumers, with potential for its experimental cholesterol drug to be offered through direct channels [4] Group 2: Previous and Current Deals - Five companies had previously made agreements with the administration to control prices, while three companies have yet to announce deals [6] - Drugmakers committed to "most-favored-nation" pricing for all new US drug launches across various markets, including Medicare [7] Group 3: Financial Commitments and Investments - Companies pledged to invest over $150 billion in US research and development and manufacturing, with Merck contributing $70 billion of that total [8] - A portion of revenues from foreign sales will be remitted to the US to help offset costs [8] Group 4: Medicaid and Market Impact - Medicaid, which represents about 10% of US drug spending, already benefits from significant price discounts, sometimes exceeding 80% [9] - Pfizer indicated that Medicaid discounts would lead to price and margin compression in the upcoming year [9]

Core Points - US President Donald Trump announced agreements with nine major pharmaceutical companies to reduce drug prices for Medicaid and cash-paying consumers, aiming to align US drug costs with those in other wealthy nations [1][4] - Trump emphasized that the US was previously subsidizing global drug costs and will no longer do so [2] Group 1: Drugmakers Involved - Participating companies include Bristol Myers Squibb, Gilead Sciences, Novartis, Amgen, Boehringer Ingelheim, Sanofi, GSK, Merck, and Roche's US unit Genentech [3] - Additional companies like Regeneron, Johnson & Johnson, and AbbVie are expected to join after the holidays [3] Group 2: Price Reductions and Commitments - Drugmakers will reduce prices on most medicines sold to Medicaid, promising "massive savings" on widely used drugs, although specific figures were not disclosed [4] - The agreements also include commitments to cut cash prices for select medicines and to launch new drugs in the US at prices equal to those in other wealthy countries [5] Group 3: Specific Drug Pricing - Merck plans to sell diabetes drugs Januvia, Janumet, and Janumet XR at discounts of about 70% off list prices [7] - Amgen will price its migraine drug Aimovig and arthritis treatment Amjevita at $299 per month, which is nearly 60% and 80% below current US list prices, respectively [7] Group 4: Investment and Revenue Sharing - Companies pledged to invest over $150 billion in US research, development, and manufacturing, with Merck alone committing $70 billion [8] - A portion of each company's overseas revenue will be remitted to the US to help offset domestic drug costs, and several companies agreed to donate drug ingredients to the US strategic reserve [9] Group 5: Industry Reaction - Five drugmakers, including Pfizer and Eli Lilly, had already struck similar deals with the administration, and AbbVie is expected to announce its agreement soon [10]

of Andrew Graham, managing partner, Jackson Square Capital, is with me to talk about the market action as we sort of wrap up this year. How are you feeling about the market right now. >> Well, I I feel like we've gone through another, you know, pullback in the momentum factor.You see that in the tech tape up until, you know, yesterday's solid solid micron report. Um, and there's follow through today. Um, I think it's kind of chopped.I guess what I'll give you a ba hug. How about that. this time of the year. ...

责任编辑：张俊 SF065 责任编辑：张俊 SF065 礼来公司（LLY）周五早盘上涨0.7%。该公司表示，在一项三期临床试验中，每日一次的orforglipron在 患者从注射型药物Wegovy和Zepbound转换后，仍能帮助维持此前的减重效果；该药已提交FDA申请， 并获优先审评资格。 礼来公司（LLY）周五早盘上涨0.7%。该公司表示，在一项三期临床试验中，每日一次的orforglipron在 患者从注射型药物Wegovy和Zepbound转换后，仍能帮助维持此前的减重效果；该药已提交FDA申请， 并获优先审评资格。 ...

US President Donald Trump is expected to announce new agreements on Friday (December 19) aimed at lowering prescription drug prices, the White House said. The announcement is scheduled for 1 p.m. ET at the White House.AbbVie, Bristol Myers Squibb, Gilead Sciences, and Merck are among the major pharmaceutical companies expected to participate, Reuters reporting citing sources familiar with the matter.Swiss drugmakers Novartis and Roche are also reportedly part of the deals, according to Bloomberg News.Backgr ...

Weight loss drug Mounjaro’s manufacturer, Eli Lilly and Co. (NYSE:LLY) has crossed a significant threshold in Benzinga Edge's Stock Rankings, moving into the top decile for quality this week. This improvement in fundamental strength coincides with a bullish note from Bank of America, which argues the market is still underestimating the pharmaceutical giant’s dominance in the obesity sector.Check out LLY’s price here.Entering The Top DecileIn the latest weekly data update, Eli Lilly's quality score advanced ...

Weight loss drug Mounjaro’s manufacturer, Eli Lilly and Co. (NYSE:LLY) has crossed a significant threshold in Benzinga Edge's Stock Rankings, moving into the top decile for quality this week. This improvement in fundamental strength coincides with a bullish note from Bank of America, which argues the market is still underestimating the pharmaceutical giant’s dominance in the obesity sector.Check out LLY’s price here.Entering The Top DecileIn the latest weekly data update, Eli Lilly's quality score advanced ...

Core Viewpoint - Eli Lilly announced an investment of over $6 billion to build a large pharmaceutical manufacturing facility in Huntsville, Alabama, which will focus on producing new generation synthetic drug active ingredients, including oral small molecule GLP-1 receptor agonist orforglipron, a key product for weight loss and metabolic diseases [6][8]. Group 1: Investment and Economic Impact - The new facility is part of Eli Lilly's plan to establish four major production sites in the U.S., with this being the third project to be launched [6]. - The project is expected to create approximately 450 high-value jobs in engineering, research, operations, and laboratory technology, with an additional 3,000 construction-related jobs during the building phase [6][8]. - For every dollar invested by Eli Lilly in the local economy, it is estimated to generate up to $4 in related economic activity growth [8]. Group 2: Technological Advancements and Strategic Direction - The facility will incorporate digital and automated systems to optimize production processes, enhance operational efficiency, and ensure higher standards of drug safety and quality [8]. - This project reflects Eli Lilly's ongoing commitment to smart manufacturing and localized supply chains, as part of its broader strategy to strengthen domestic production capabilities amid global pharmaceutical supply chain restructuring [8]. Group 3: Broader Expansion Plans - The Alabama project is part of a larger expansion plan, with Eli Lilly also announcing new production facilities in Texas and Virginia, as well as expansions of existing facilities in Puerto Rico [8]. - Further announcements regarding additional U.S. production sites are expected in the coming weeks [8].